UNSPSC 51171917: Ranitidine

This classification denotes a histamine-2 receptor antagonist with the molecular formula C19H27BiN4O10S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7AJ51I17KG, chemically known as bismuth;(E)-1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine;2-hydroxypropane-1,2,3-tricarboxylate but generally known as ranitidine bismuth citrate, which bears US NIH Compound Identifier 3033887.

UNSPSC 51171917 Ranitidine (Commodity) represents pharmaceutical products actively procured by state and local public health, corrections, and benefits agencies, though recent solicitations show the code captures a broader spectrum of drug-testing services and generic pharmaceutical supply chains rather than ranitidine specifically. State and local governments buy drug-testing services under this taxonomy — including specimen collection, immunoassay screening with confirmatory testing (LC/MS/MS and GC/MS), oral fluid and hair testing methodologies, and related laboratory operations — as well as generic multi-source pharmaceuticals and over-the-counter products distributed through wholesaler networks to state facilities and participating public health systems. Issuing bodies include county corrections departments (Collin County Community Supervision and Corrections Department in Texas), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP), reflecting demand from criminal justice, public health, and employee benefits programs.

Recent activity centers in Texas and the upper Midwest. Collin County, Texas issued RFP 2026-327 for Offender Specimen Collection and Drug Testing Services on July 9, 2026, with proposals due July 23, 2026; the scope encompasses staffing two collection sites (Plano and McKinney), approximately 25,031 annual tests across five- and six-panel screens, lab certification from SAMHSA or Texas DPS, a $600,000 estimated value, and a two-year initial term with three optional one-year renewals. The Texas HHS Commission issued RFI HHS0017013 on March 27, 2026 (response due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program — a preliminary market-intelligence phase preceding formal RFP issuance. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026; the contract term is two years with optional extensions, requires cGMP and DSCSA compliance, and mandates relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson).